News Quantified


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Natera (NTRA) is now covered by William Blair. They set an "outperform" rating on the stock.

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents

Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller [Yahoo! Finance]

20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform

2/26/2026

04:05 pm

NTRA

-3.5%

MISS

11/6/2025

04:05 pm

NTRA

0.5%

MISS

8/7/2025

04:05 pm

NTRA

7.7%

MISS

5/8/2025

04:05 pm

NTRA

-7.3%

BEAT

Form 3 Natera, Inc. For: Mar 26 Filed by: Rubin Eric H

Form 4 Natera, Inc. For: Apr 06 Filed by: Rabinowitz Matthew

Form 4 Natera, Inc. For: Apr 01 Filed by: RABINOWITZ DANIEL

Form 4 Natera, Inc. For: Apr 01 Filed by: Moshkevich Solomon

Form 4 Natera, Inc. For: Mar 31 Filed by: Rabinowitz Matthew

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}